Pivotal topline results from the CAMPSIITE® trial of RGX-121 for the treatment of MPS II to be presented Conference call Wednesday, February 7, 4:30 p.m. ET ROCKVILLE, Md., Jan. 31, 2024 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its program for the…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.